Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment
Key claim: Nature.com reports that integrating proteomic aging clocks into a phase 2a clinical trial supports simultaneous assessment of geroprotective effects.
Abstract
News coverage by nature.com: “Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment”. Headline and link only — this finding reports press coverage of a government action, not the primary record.
Why this matters
Embedding proteomic aging clocks as endpoints inside a phase 2a trial is the kind of measurement-layer step that determines whether geroprotector candidates get concurrent biological-age readouts alongside classical clinical endpoints. It matters for this area because trial-embedded clocks are how consumer-facing ‘de-aging’ claims will eventually be adjudicated — but only if the clocks used have independent predictive validity, and clock movement is not itself evidence of slowed aging.